187 related articles for article (PubMed ID: 11023525)
1. Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Zwaan CM; Kaspers GJ; Pieters R; Ramakers-Van Woerden NL; den Boer ML; Wünsche R; Rottier MM; Hählen K; van Wering ER; Janka-Schaub GE; Creutzig U; Veerman AJ
Blood; 2000 Oct; 96(8):2879-86. PubMed ID: 11023525
[TBL] [Abstract][Full Text] [Related]
2. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
[TBL] [Abstract][Full Text] [Related]
3. In vitro efficacy of l-asparaginase in childhood acute myeloid leukaemia.
Okada S; Hongo T; Yamada S; Watanabe C; Fujii Y; Ohzeki T; Horikoshi Y; Ito T; Yazaki M; Komada Y; Tawa A
Br J Haematol; 2003 Dec; 123(5):802-9. PubMed ID: 14632770
[TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia.
Yamada S; Hongo T; Okada S; Watanabe C; Fujii Y; Ohzeki T
Leukemia; 2001 Dec; 15(12):1892-7. PubMed ID: 11753610
[TBL] [Abstract][Full Text] [Related]
5. Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Huismans DR; Zimmermann M; Harbott J; Slater RM; Creutzig U; Veerman AJ
Blood; 2002 Nov; 100(9):3352-60. PubMed ID: 12384437
[TBL] [Abstract][Full Text] [Related]
6. FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia.
Nørgaard JM; Olesen LH; Olesen G; Meyer K; Kristensen JS; Bendix K; Pedersen B; Kjeldsen E; Hokland P
Eur J Haematol; 2001 Oct; 67(4):221-9. PubMed ID: 11860442
[TBL] [Abstract][Full Text] [Related]
7. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia.
Styczynski J; Pieters R; Huismans DR; Schuurhuis GJ; Wysocki M; Veerman AJ
Br J Haematol; 2000 Sep; 110(4):813-8. PubMed ID: 11054062
[TBL] [Abstract][Full Text] [Related]
9. In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
Hubeek I; Peters GJ; Broekhuizen R; Zwaan CM; Kaaijk P; van Wering ES; Gibson BE; Creutzig U; Janka-Schaub GE; den Boer ML; Pieters R; Kaspers GJ
Haematologica; 2006 Jan; 91(1):17-23. PubMed ID: 16434366
[TBL] [Abstract][Full Text] [Related]
10. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia.
Klumper E; Pieters R; Veerman AJ; Huismans DR; Loonen AH; Hählen K; Kaspers GJ; van Wering ER; Hartmann R; Henze G
Blood; 1995 Nov; 86(10):3861-8. PubMed ID: 7579354
[TBL] [Abstract][Full Text] [Related]
11. [Drug sensitivity of tumor cells in varieties of acute childhood leukemia].
Shman TV; Belevtsev MV; Buglova SE
Vopr Onkol; 2005; 51(5):558-62. PubMed ID: 16756010
[TBL] [Abstract][Full Text] [Related]
12. In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Goemans BF; Zwaan CM; Harlow A; Loonen AH; Gibson BE; Hählen K; Reinhardt D; Creutzig U; Heinrich MC; Kaspers GJ
Blood; 2005 Nov; 106(10):3532-7. PubMed ID: 16051737
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia-FAB classification and its correlation with clinico-haematological features.
Hassan K; Qureshi M; Shafi S; Ikram N; Akhtar MJ
J Pak Med Assoc; 1993 Oct; 43(10):200-3. PubMed ID: 8114248
[TBL] [Abstract][Full Text] [Related]
14. Two groups of Philadelphia chromosome-positive childhood acute lymphoblastic leukemia classified by pretreatment multidrug sensitivity or resistance in in vitro testing.
Hongo T; Okada S; Inoue N; Yamada S; Yajima S; Watanabe C; Fujii Y; Horikoshi Y
Int J Hematol; 2002 Oct; 76(3):251-9. PubMed ID: 12416736
[TBL] [Abstract][Full Text] [Related]
15. Clinical and cell biological features related to cellular drug resistance of childhood acute lymphoblastic leukemia cells.
Kaspers GJ; Pieters R; Van Zantwijk CH; Van Wering ER; Veerman AJ
Leuk Lymphoma; 1995 Nov; 19(5-6):407-16. PubMed ID: 8590840
[TBL] [Abstract][Full Text] [Related]
16. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
[TBL] [Abstract][Full Text] [Related]
17. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in pediatric acute lymphoblastic and myeloid leukemia.
Ravindranath Y
Curr Opin Oncol; 2003 Jan; 15(1):23-35. PubMed ID: 12490758
[TBL] [Abstract][Full Text] [Related]
19. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia.
Kaspers GJ; Veerman AJ; Pieters R; Van Zantwijk CH; Smets LA; Van Wering ER; Van Der Does-Van Den Berg A
Blood; 1997 Oct; 90(7):2723-9. PubMed ID: 9326239
[TBL] [Abstract][Full Text] [Related]
20. Drug-resistance Profile in Multiple-relapsed Childhood Acute Lymphoblastic Leukemia.
Pogorzala M; Kubicka M; Rafinska B; Wysocki M; Styczynski J
Anticancer Res; 2015 Oct; 35(10):5667-70. PubMed ID: 26408741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
